within Pharmacolibrary.Drugs.ATC.L;

model L01EX21
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.72,
    Cl             = 3.6666666666666666e-05,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0019299999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007833333333333333,
    Tlag           = 60,            
    Vdp             = 0.00091,
    k12             = 1.78,
    k21             = 1.78
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EX21</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tepotinib is a selective MET inhibitor used for the treatment of adult patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. It is an orally administered targeted therapy that inhibits the hepatocyte growth factor (HGF)/MET signaling pathway. Tepotinib is approved in several countries, including the United States and the European Union.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for adult patients with advanced solid tumors and NSCLC after oral administration.</p><h4>References</h4><ol><li><p>Xiong, W, et al., &amp; Girard, P (2022). Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study. <i>Cancer chemotherapy and pharmacology</i> 89(5) 655–669. DOI:<a href=\"https://doi.org/10.1007/s00280-022-04423-5\">10.1007/s00280-022-04423-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35385993/\">https://pubmed.ncbi.nlm.nih.gov/35385993</a></p></li><li><p>Johne, A, et al., &amp; Meyring, M (2020). Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers. <i>Investigational new drugs</i> 38(5) 1507–1519. DOI:<a href=\"https://doi.org/10.1007/s10637-020-00926-1\">10.1007/s10637-020-00926-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32221754/\">https://pubmed.ncbi.nlm.nih.gov/32221754</a></p></li><li><p>Xiong, W, et al., &amp; El Bawab, S (2021). Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 10(5) 428–440. DOI:<a href=\"https://doi.org/10.1002/psp4.12602\">10.1002/psp4.12602</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33818908/\">https://pubmed.ncbi.nlm.nih.gov/33818908</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EX21;
